RA Capital Management, a prominent life-sciences investor, revealed a new holding in Hemab Therapeutics (COAG) in a recent disclosure. The filing, which reflects positions held as of June 30, 2026, showed the firm acquired 7.81 million shares valued at approximately $286.8 million. This new investment gives RA Capital a 2.49% weight in the newly public company within its reported portfolio.

Hemab Therapeutics is a clinical-stage biotech company focused on developing treatments for rare bleeding and thrombotic disorders. The company completed its upsized initial public offering in early May 2026, raising gross proceeds of about $346.7 million. As with all 13F filings, this disclosure reflects a position held at the end of the previous quarter, and the transactions occurred at an undisclosed time during the three months ending in June.